Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading.
Artificial intelligence
Grading
Pathology
Prostate cancer
Reproducibility
Standardization
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
12
05
2020
accepted:
28
05
2020
revised:
21
05
2020
pubmed:
17
6
2020
medline:
15
12
2020
entrez:
17
6
2020
Statut:
ppublish
Résumé
The International Society of Urological Pathology (ISUP) hosts a reference image database supervised by experts with the purpose of establishing an international standard in prostate cancer grading. Here, we aimed to identify areas of grading difficulties and compare the results with those obtained from an artificial intelligence system trained in grading. In a series of 87 needle biopsies of cancers selected to include problematic cases, experts failed to reach a 2/3 consensus in 41.4% (36/87). Among consensus and non-consensus cases, the weighted kappa was 0.77 (range 0.68-0.84) and 0.50 (range 0.40-0.57), respectively. Among the non-consensus cases, four main causes of disagreement were identified: the distinction between Gleason score 3 + 3 with tangential cutting artifacts vs. Gleason score 3 + 4 with poorly formed or fused glands (13 cases), Gleason score 3 + 4 vs. 4 + 3 (7 cases), Gleason score 4 + 3 vs. 4 + 4 (8 cases) and the identification of a small component of Gleason pattern 5 (6 cases). The AI system obtained a weighted kappa value of 0.53 among the non-consensus cases, placing it as the observer with the sixth best reproducibility out of a total of 24. AI may serve as a decision support and decrease inter-observer variability by its ability to make consistent decisions. The grading of these cancer patterns that best predicts outcome and guides treatment warrants further clinical and genetic studies. Results of such investigations should be used to improve calibration of AI systems.
Identifiants
pubmed: 32542445
doi: 10.1007/s00428-020-02858-w
pii: 10.1007/s00428-020-02858-w
pmc: PMC7683442
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
777-786Subventions
Organisme : Cancerfonden
ID : CAN 2017/270
Commentaires et corrections
Type : CommentIn
Références
Histopathology. 2018 Jul;73(1):8-18
pubmed: 29359484
Am J Surg Pathol. 2015 Oct;39(10):1331-9
pubmed: 26099009
Histopathology. 2006 May;48(6):644-54
pubmed: 16681679
N Engl J Med. 2016 Sep 29;375(13):1216-9
pubmed: 27682033
Nat Rev Urol. 2019 Jul;16(7):391-403
pubmed: 31092914
BJU Int. 2017 Nov;120(5):651-658
pubmed: 28371244
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
World J Urol. 2007 Dec;25(6):595-605
pubmed: 17828603
Histopathology. 2016 Sep;69(3):441-9
pubmed: 27028587
Hum Pathol. 2001 Jan;32(1):81-8
pubmed: 11172299
Am J Surg Pathol. 2013 Dec;37(12):1855-61
pubmed: 24145642
Lancet Oncol. 2020 Feb;21(2):222-232
pubmed: 31926806
Hum Pathol. 2001 Jan;32(1):74-80
pubmed: 11172298
Pathology. 2015 Oct;47(6):520-5
pubmed: 26325671
J Urol. 2004 Feb;171(2 Pt 1):664-7
pubmed: 14713782
Lancet Oncol. 2015 Dec;16(16):1667-76
pubmed: 26563502
Eur Urol. 2016 Apr;69(4):592-598
pubmed: 26542947
Lancet Oncol. 2019 May;20(5):e253-e261
pubmed: 31044723
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
Histopathology. 2013 Jan;62(2):247-56
pubmed: 23240715
Histopathology. 2017 Nov;71(5):677-685
pubmed: 28722802
Br J Cancer. 2016 May 10;114(10):1078-83
pubmed: 27100731